CODX - Co-Diagnostics Inc
(NaN%)
Hold
Moderate Growth and Improving
58%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 120.2%
Operating Income Growth is 115.4%
Net Income Growth is 50.22%
Earnings Per Share (EPS) Growth is 59.55%
Net Margin is 40.11%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 24.83
Debt Ratio is 0.05
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is WEAK
Cash from Operations Growth is 751.55%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is POSITIVE
Investment Risk is Low
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Co-Diagnostics Inc (CODX) - codiagnostics.com
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.Exchange - NASDAQ
Industry - Surgical and Medical Instrument Manufacturing
Sector - Manufacturing
CEO - Dwight Egan
Employees - 37
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.